Tweet
Good morning friends.
Having been hospitalized several times with AF, I stay on the lookout for treatments that are coming down the pike. This one caught my eye as the last time I was in they suggested switching me to amiodarone. I pulled this of the medscape website I posted about a month or so ago.
Peace,
Leon
Positive Results Seen With Investigational Antiarrhythmic for Atrial Fibrillation
MUNICH (Reuters) Aug 30 - A new antiarrhythmic, dronedarone (Sanofi-Aventis), significantly reduces the risk of atrial fibrillation, according to the results of two clinical studies released on Sunday.
The trials showed that patients given dronedarone went, on average, 2.3 and 2.7 times longer than those on placebo before experiencing atrial fib. The risk of a first occurrence was also reduced significantly, by 21.6% and 27.5%, over a one-year period.
There was, however, no significant reduction on mortality in the phase III studies, which involved a total of 1,507 patients.
"The results of the ADONIS and EURIDIS trials appear to position dronedarone as a promising option for ... rate control in atrial fibrillation," Stefan Hohnloser of JW Goethe University in Frankfurt told the annual meeting of the European Society of Cardiology.
Dronedarone is a modification of amiodarone, which has been linked to organ toxicity. Because of its problems, many physicians have been reluctant to use amiodarone except as a second-line therapy.
Hohnloser, an investigator on the EURIDIS trial, said dronedarone showed no such problems.
Dronedarone suffered a setback in another trial last year when it failed to demonstrate benefit in patients with congestive heart failure.
Having been hospitalized several times with AF, I stay on the lookout for treatments that are coming down the pike. This one caught my eye as the last time I was in they suggested switching me to amiodarone. I pulled this of the medscape website I posted about a month or so ago.
Peace,
Leon
Positive Results Seen With Investigational Antiarrhythmic for Atrial Fibrillation
MUNICH (Reuters) Aug 30 - A new antiarrhythmic, dronedarone (Sanofi-Aventis), significantly reduces the risk of atrial fibrillation, according to the results of two clinical studies released on Sunday.
The trials showed that patients given dronedarone went, on average, 2.3 and 2.7 times longer than those on placebo before experiencing atrial fib. The risk of a first occurrence was also reduced significantly, by 21.6% and 27.5%, over a one-year period.
There was, however, no significant reduction on mortality in the phase III studies, which involved a total of 1,507 patients.
"The results of the ADONIS and EURIDIS trials appear to position dronedarone as a promising option for ... rate control in atrial fibrillation," Stefan Hohnloser of JW Goethe University in Frankfurt told the annual meeting of the European Society of Cardiology.
Dronedarone is a modification of amiodarone, which has been linked to organ toxicity. Because of its problems, many physicians have been reluctant to use amiodarone except as a second-line therapy.
Hohnloser, an investigator on the EURIDIS trial, said dronedarone showed no such problems.
Dronedarone suffered a setback in another trial last year when it failed to demonstrate benefit in patients with congestive heart failure.
Comment